HP
48
3
M
37
12
MAT
46
12
LB
63
22
ADBE
49
3
KLAC
47
4
LLY
37
-3
CSCO
67
4
CMA
61
5
TDC
80
4
STI
14
-17
SLB
55
2
EXC
53
-3
AAP
24
6
XRAY
28
2
COF
60
2
PEP
48
6
A
43
2
NRG
49
-3
GIS
31
3
HP
48
3
M
37
12
MAT
46
12
LB
63
22
ADBE
49
3
KLAC
47
4
LLY
37
-3
CSCO
67
4
CMA
61
5
TDC
80
4
STI
14
-17
SLB
55
2
EXC
53
-3
AAP
24
6
XRAY
28
2
COF
60
2
PEP
48
6
A
43
2
NRG
49
-3
GIS
31
3
Financhill
Back

Sarepta Therapeutics 10K Form

Sell
33

SRPT
Sarepta Therapeutics

Last Price:
114.28
Seasonality Move:
16.38%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive SRPT News And Ratings

See the #1 stock for the next 7 days that we like better than SRPT

SRPT Financial Statistics

Sales & Book Value

Annual Sales: $1.24B
Cash Flow: $-107.96M
Price / Cash Flow: 0
Annual Sales: $12.79
Price / Book: 8.94

Profitability

EPS (TTM): 1.54000
Net Income (TTM): $121.85M
Gross Margin: $1.09B
Return on Equity: 12.48%
Return on Assets: 3.67%

Sarepta Therapeutics Earnings Forecast

Key Sarepta Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 28 years for SRPT is 87.91%.
  • The Selling, General & Administrative Expenses for SRPT have been equal to 38.76% of Gross Profit Margin.
  • The Research & Development expenses have been 70.57% of Revenue.
  • The Interest Expense is -4.11% of Operating Income.
  • The Net Earning history of SRPT is -43.11% of Total Revenues.
  • Per Share Earnings over the last 28 years have been positive in 14 years.

Sarepta Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: SRPT
CUSIP: 803607
Website: sarepta.com

Debt

Debt-to-Equity Ratio: 1.01
Current Ratio: 3.84
Quick Ratio: 2.45

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 9.1

SRPT Technical Analysis vs Fundamental Analysis

Sell
33
Sarepta Therapeutics (SRPT) is a Sell

Is Sarepta Therapeutics a Buy or a Sell?